Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspira Pathlab & DiagnosticsBOM:540788 -1.97%51 Quick Ratio is 1.22 as of Mar. 2026, which is 18% below its 10-year median of 1.49. GuruFocus rates BOM:540788 with a GF Score™ of 51/100 and a GF Value™ of ₹70.73 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 212 Medical Diagnostics & Research companies, Aspira Pathlab & Diagnostics ranks worse than 67.45% on this metric.
Aspira Pathlab & Diagnostics has a quick ratio of 1.22. It generally indicates good short-term financial strength.
The historical rank and industry rank for Aspira Pathlab & Diagnostics's Quick Ratio or its related term are showing as below:
BOM:540788'
s Quick Ratio Range Over the Past 10 Years
Min: 0.48 Med: 1.49 Max: 3.77
Current: 1.22
During the past 13 years, Aspira Pathlab & Diagnostics's highest Quick Ratio was 3.77. The lowest was 0.48. And the median was 1.49.
BOM:540788's Quick Ratio is ranked worse than 67.45% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.755
vs BOM:540788: 1.22
Aspira Pathlab & Diagnostics (BOM:540788) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Aspira Pathlab & Diagnostics Quick Ratio Related Terms
Aspira Pathlab & Diagnostics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540788 vs TMO, DHR, IDXX: Quick Ratio Comparison
For the Diagnostics & Research subindustry, Aspira Pathlab & Diagnostics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Pathlab & Diagnostics Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Pathlab & Diagnostics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Aspira Pathlab & Diagnostics's Quick Ratio falls into.
Aspira Pathlab & Diagnostics Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Pathlab & Diagnostics (BOM:540788) has a Quick Ratio of 1.22 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aspira Pathlab & Diagnostics and its competitors. This is 18% below median its historical median of 1.49. Over the past decade, Aspira Pathlab & Diagnostics' Quick Ratio has ranged from 0.48 to 3.77. According to the industry distribution chart, Aspira Pathlab & Diagnostics ranks #143 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 67.5%.
Is Aspira Pathlab & Diagnostics' Quick Ratio too high?
Aspira Pathlab & Diagnostics' current Quick Ratio of 1.22 is 18% below median its 10-year median of 1.49. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 3.77. The Medical Diagnostics & Research industry median Quick Ratio is 1.76. Aspira Pathlab & Diagnostics' value of 1.22 is 30.5% below this industry median. Based on the distribution chart, Aspira Pathlab & Diagnostics ranks #143 out of 212 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Aspira Pathlab & Diagnostics has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Pathlab & Diagnostics' Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Pathlab & Diagnostics ranks #143 out of 212 companies for Quick Ratio. This places Aspira Pathlab & Diagnostics in the lower half of its industry. The industry median Quick Ratio is 1.76. Aspira Pathlab & Diagnostics' value of 1.22 is 30.5% below this benchmark. Historically, Aspira Pathlab & Diagnostics' own Quick Ratio has ranged from 0.48 to 3.77 over the past decade. While the company's 10-year median is 1.49 vs. the industry median of 1.76, Aspira Pathlab & Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.76, based on 212 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Pathlab & Diagnostics's current Quick Ratio of 1.22 is 30.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aspira Pathlab & Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Pathlab & Diagnostics's current Quick Ratio is 1.22, which is 18% below median its own 10-year median of 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Pathlab & Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics (BOM:540788) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹70.73, compared to a current price of ₹106.90 — trading 51.1% above its estimated fair value. The current Quick Ratio is 1.22, which is 18% below median its 10-year median of 1.49 and 30.5% below the Medical Diagnostics & Research industry median of 1.76. Aspira Pathlab & Diagnostics' overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Aspira Pathlab & Diagnostics (BOM:540788), the current Quick Ratio is 1.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Pathlab & Diagnostics (BOM:540788) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics stock appears to be overvalued.
The current stock price of ₹106.90 is trading 51.1% above its estimated GF Value™ of ₹70.73.
GuruFocus considers Aspira Pathlab & Diagnostics to be Significantly Overvalued.
Key valuation signals for BOM:540788:
Quick Ratio: 1.22 (18% below median its 10-year median of 1.49)
GF Value™: ₹70.73 vs. price of ₹106.90 (51.1% above fair value)
Industry Position: 30.5% below the Medical Diagnostics & Research median (#143 of 212)
No single metric tells the full story. See the BOM:540788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Pathlab & Diagnostics Ltd is mainly engaged in pathology and related healthcare services. It operates laboratories that conduct a wide range of pathological investigations across branches such as biochemistry, hematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology, and other pathological and radiological tests. The services offered include pathology tests, sonography, X-rays, and radiology. The company also provides various health packages like gynecology profiles, anemia profiles, monsoon profiles, coagulation tests, cancer screening packages, newborn screening and IEM panels, orthopedic profiles, allergy panels, and cardiac profiles. These comprehensive diagnostic services assist in disease diagnosis.
51GF Score
Get the complete analysis for BOM:540788
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540788 has been successfully added to your 
